Fig. 2From: Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in CanadaKaplan-Meier curve and fitted log-logistic parametric curves from combined analysis for progression-free survival (PFS) among ROS1+ NSCLC patientsBack to article page